These results highlight that aberrant astrocytic Mysm1 functions as a potential molecular mechanism underlying MDD pathophysiology, and suggest that astrocytic Mysm1 could serve as a potential target for new therapeutic interventions against depressive disorders. Here, MYSM1 is linked to major depressive disorder.